DE69738459D1 - Hemmung des Wachstums der chronischen Myelogenen leukämischen Zellen durch antisens-Oligonukleotide die an Crkl zielgerichtet sind - Google Patents

Hemmung des Wachstums der chronischen Myelogenen leukämischen Zellen durch antisens-Oligonukleotide die an Crkl zielgerichtet sind

Info

Publication number
DE69738459D1
DE69738459D1 DE69738459T DE69738459T DE69738459D1 DE 69738459 D1 DE69738459 D1 DE 69738459D1 DE 69738459 T DE69738459 T DE 69738459T DE 69738459 T DE69738459 T DE 69738459T DE 69738459 D1 DE69738459 D1 DE 69738459D1
Authority
DE
Germany
Prior art keywords
antisense oligonucleotides
chronic myelogenous
crkl
inhibition
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738459T
Other languages
English (en)
Other versions
DE69738459T2 (de
Inventor
Ralph B Arlinghaus
Ana M Tari
Gabriel Lopez-Berestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of DE69738459D1 publication Critical patent/DE69738459D1/de
Application granted granted Critical
Publication of DE69738459T2 publication Critical patent/DE69738459T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
DE69738459T 1996-07-08 1997-07-08 Hemmung des Wachstums der chronischen Myelogenen leukämischen Zellen durch antisens-Oligonukleotide die an Crkl zielgerichtet sind Expired - Lifetime DE69738459T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/679,437 US7309692B1 (en) 1996-07-08 1996-07-08 Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US679437 1996-07-08

Publications (2)

Publication Number Publication Date
DE69738459D1 true DE69738459D1 (de) 2008-02-21
DE69738459T2 DE69738459T2 (de) 2008-12-24

Family

ID=24726909

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69738459T Expired - Lifetime DE69738459T2 (de) 1996-07-08 1997-07-08 Hemmung des Wachstums der chronischen Myelogenen leukämischen Zellen durch antisens-Oligonukleotide die an Crkl zielgerichtet sind
DE69736290T Expired - Lifetime DE69736290T2 (de) 1996-07-08 1997-07-08 Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens-oligonukleotide die an grb2 zielgerichtet sind

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69736290T Expired - Lifetime DE69736290T2 (de) 1996-07-08 1997-07-08 Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens-oligonukleotide die an grb2 zielgerichtet sind

Country Status (9)

Country Link
US (3) US7309692B1 (de)
EP (2) EP1234876B1 (de)
JP (1) JP2000514438A (de)
AT (2) ATE332369T1 (de)
AU (1) AU740289B2 (de)
CA (2) CA2259144C (de)
DE (2) DE69738459T2 (de)
ES (2) ES2299536T3 (de)
WO (1) WO1998001547A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062911A2 (en) * 2000-02-24 2001-08-30 Ribozyme Pharmaceuticals, Inc. Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses
WO2006113679A2 (en) 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
EP2306978A2 (de) * 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Zusammensetzungen zur abgabe von rnai-mitteln in vivo
EP2303913A4 (de) * 2008-06-20 2013-07-24 Univ Texas Auf crkl zielende peptide
WO2017066643A1 (en) 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
MX2019003070A (es) 2016-09-16 2019-10-14 Bio Path Holdings Inc Terapia de combinacion con oligonucleotidos antisentido liposomales.
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (de) 1977-08-05 1981-02-13 Battelle Memorial Institute
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5094785A (en) 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
WO1990012595A1 (en) 1989-04-18 1990-11-01 Vestar, Inc. Liposomal targeting of ischemic tissue
CA2033725C (en) 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
ATE151076T1 (de) 1990-07-02 1997-04-15 Hoechst Ag Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-internucleotidverknüpfungen
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
FR2710074B1 (fr) 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
EP0721503A1 (de) 1993-09-28 1996-07-17 The General Hospital Corporation Gebrauch von "antisense"-oligonukleotiden zur modulierung des nerven-wachstums und zum umkehren von beta/a4-induzierte morphologie
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
CA2113494A1 (en) 1994-01-14 1995-07-15 Lorri Puil Method for assaying for substances which affect bcr-abl mediated transformation
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5667981A (en) 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
WO1996038176A1 (fr) 1995-06-01 1996-12-05 Kishimoto, Tadamitsu Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1)
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
ATE247971T1 (de) 1995-08-01 2003-09-15 Novartis Erfind Verwalt Gmbh Liposomale oligonukleotidzusammensetzungen
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
AU4510396A (en) 1995-12-04 1997-06-27 Human Genome Sciences, Inc. Growth factor receptor-binding protein 2 homolog
US5874224A (en) 1997-03-11 1999-02-23 Incyte Pharmaceuticals, Inc. Growth factor receptor binding protein
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9711919D0 (en) 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
WO1998058630A1 (en) 1997-06-23 1998-12-30 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
US6277981B1 (en) 1997-07-03 2001-08-21 Thomas Jefferson University Method for design and selection of efficacious antisense oligonucleotides
US6136965A (en) 1998-07-02 2000-10-24 The Regents Of The University Of California Deoxynucleic alkyl and alkoxy thiourea compounds
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6323487B1 (en) * 1999-01-26 2001-11-27 Delphi Technologies, Inc. IR optical position sensor system
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Also Published As

Publication number Publication date
US7309692B1 (en) 2007-12-18
AU740289B2 (en) 2001-11-01
CA2259144A1 (en) 1998-01-15
US7220853B2 (en) 2007-05-22
EP0912729A1 (de) 1999-05-06
DE69736290T2 (de) 2007-07-05
WO1998001547A1 (en) 1998-01-15
DE69738459T2 (de) 2008-12-24
US7923548B2 (en) 2011-04-12
ES2299536T3 (es) 2008-06-01
CA2259144C (en) 2011-09-20
EP1234876A1 (de) 2002-08-28
EP0912729B1 (de) 2006-07-05
US20070238686A1 (en) 2007-10-11
ATE332369T1 (de) 2006-07-15
DE69736290D1 (de) 2006-08-17
EP1234876B1 (de) 2008-01-09
ATE383422T1 (de) 2008-01-15
US20030153526A1 (en) 2003-08-14
ES2268731T3 (es) 2007-03-16
JP2000514438A (ja) 2000-10-31
AU3569497A (en) 1998-02-02
CA2741501A1 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
DE69736432D1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP2796554A3 (de) Zusammensetzungen zur Behandlung von BCL2-assoziiertem Krebs
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
ATE508188T1 (de) Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
AU2002351196A1 (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
DK1296714T3 (da) Kombination af CpG og antistoffer, der er rettet mod CD19, CD20, CD22 eller CD40 til behandling eller forebyggelse af kræft
DE69431164D1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
WO2005047477A3 (en) Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
WO2003048315A3 (en) Antisense modulation of mdm2 expression
ATE488529T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
DE69738459D1 (de) Hemmung des Wachstums der chronischen Myelogenen leukämischen Zellen durch antisens-Oligonukleotide die an Crkl zielgerichtet sind
WO2003100000A3 (en) Amplification and overexpression of oncogenes
EP1570081A4 (de) An krebs beteiligte amplifizierte gene
CA2417874A1 (en) Use of ox-2 inhibitors for the treatment of cancer
WO2004076445A3 (en) Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
EP0924296A3 (de) Verfahren un Mittteln für die Induktion von Apoptosis durch Interferenz in RNS-Prozessierung
EP1427418A4 (de) Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel und behandlungsverfahren
WO2003044161A3 (en) Gene amplification and overexpression in cancer
WO2006066154A3 (en) Casein kinase 2 antisense therapy
WO2001060998A3 (en) Small oligonucleotides with anti-tumor activity
EP1234877A4 (de) Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie
WO2005030225A3 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
MXPA05008817A (es) Derivados de esteres lipidos de nucleotidos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition